Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient was previously diagnosed with multiple myeloma based on standard criteria and currently requires second or \*third line therapy because of PD, defined as a 25% increase in M-protein, or development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium \>11.5 mg/dL), or relapse from CR.\*Patients will only be eligible for bortezomib as 3rd line therapy if they have received dexamethasone alone, thalidomide alone (or with corticosteroids) or revlimid alone (or with corticosteroids) as one of the 2 prior therapies.~* Patient is of a legally consenting age, as defined by local regulations.~* Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.~* Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.~* Female patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.~* Male patient agrees to use an acceptable method for contraception for the duration of the study.~* Patient has measurable disease~* Patient has a Karnofsky performance status ≥60%.~* Patient has a life-expectancy \>3 months.~Exclusion Criteria:~* Primary Dexamethasone resistance~* Prior therapy with Bortezomib~* Prior severe allergic reactions to Bortezomib (Velcade), Boron or Mannitol~* Neuropathy \> Grade 2 with pain by NCI-CTCAE criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bortezomib and Dexamethasone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).